论文部分内容阅读
目的探讨外周血造血干细胞(PBSC)动员采集的方法及其效果。方法对恶性血液病(多发性骨髓瘤、急性白血病和淋巴瘤)患者及健康供者经单一粒细胞集落刺激因子(G-CSF)和化疗联合粒细胞集落刺激因子方案动员后,使用血细胞分离机采集外周血造血干细胞,分析不同动员方案、疾病、年龄、性别及供者的动员采集。结果所有患者和健康供者均成功动员和采集到了PBSC(MNC>5×108/kg,CD34+>2×106/kg);健康供者的动员效果为MNC(8.25±3.07)×109/L;恶性血液病患者中,急性髓细胞白血病患者采集所获得的MNC最多,为(7.48±2.62)×108/kg,多发性骨髓瘤患者最差,为(5.06±1.50)×108/kg;急性淋巴细胞白血病患者采集所获得的CD34+最多,为(5.36±2.64)×106/kg,多发性骨髓瘤患者最少,为(3.45±0.76)×106/kg。化疗联合G-CSF和IL-11为最好的动员方案;18—60岁患者采集效果最好,60—65岁患者最差;男性较女性好。结论健康供者较恶性血液病患者动员效果好,健康供者中性别对采集效果无影响;无论是健康供者还是恶性血液病患者,动员、采集过程副作用小。
Objective To investigate the method and effect of peripheral blood stem cell (PBSC) mobilization and collection. Methods After mobilization of patients with hematologic malignancies (multiple myeloma, acute leukemia and lymphoma) and healthy donors by single granulocyte colony-stimulating factor (G-CSF) and chemotherapy combined with granulocyte colony-stimulating factor, Peripheral blood hematopoietic stem cells were collected and analyzed for mobilization and collection of different mobilization programs, diseases, age, gender and donor. Results All patients and healthy donors mobilized and collected PBSC (MNC> 5 × 108 / kg, CD34 +> 2 × 106 / kg). The mobilization effect of healthy donors was MNC (8.25 ± 3.07) × 109 / L; Among the patients with hematologic malignancies, the average number of MNCs collected in patients with acute myeloid leukemia was (7.48 ± 2.62) × 108 / kg, the worst among multiple myeloma patients was (5.06 ± 1.50) × 108 / kg; acute lymphoid The highest number of CD34 + cells collected in patients with leukemia was (5.36 ± 2.64) × 106 / kg, with the lowest number of patients with multiple myeloma (3.45 ± 0.76) × 106 / kg. Chemotherapy combined with G-CSF and IL-11 are the best mobilization regimens; 18- to 60-year-olds are the best, 60-65 year-olds are the worst, and men are better than women. Conclusion The mobilization effect is better in patients with hematological malignancies than those in healthy donors. The gender of healthy donors has no effect on the efficacy of hematological malignancies. Both of them have fewer side effects during mobilization and collection of hematological malignancies.